Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer

Zenzola, Victor; Cabezas-Quintario, María Antonia; Arguelles, M.; Pérez‐Fernández, Elia; Izarzugaza, Yann; Correa, Andrea; García‐Foncillas, Jesús

doi:10.1007/s12094-018-1877-5

Cited by 17 publications

(17 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ki-67 and family history of breast cancer and other cancers are considered useful in the prognosis of TNBC 18 . Nevertheless, the literature indicates that there is controversy surrounding the methods used for analysis of these prognostic factors 9,18 . In this study, Ki-67 (with a cutoff point stipulated at 60%) and a family history of breast cancer and other cancers were not implicated in a significant decrease in OS and/or DFS and increased risk of mortality and/or recurrence.…”

Section: Discussionmentioning

confidence: 99%

“…In the literature, diverse prognostic factors have been associated with TNBC, including recurrence, lymphovascular invasion, tumor size, lymph node involvement, and Ki-67 expression, among others 8,9 . The prognostic value of Ki-67 in TNBC remains controversial, partly due to the lack of agreement on the cutoff point, which is estimated at 10-61% 9 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic factors in triple-negative breast cancer: a retrospective cohort

Costa

Oliveira

Araújo³

et al. 2021

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

OBJECTIVE: Triple-negative breast cancer (TNBC) is characterized by lack of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expression and accounts for 15-20% of all breast cancers. This study aims to analyze prognostic factors related to a reduction in overall survival (OS), disease-free survival (DFS), and risk of mortality and recurrence in TNBC.METHODS: This is a retrospective observational cohort study. Medical records of 532 patients with breast cancer diagnosed from 2007 to 2020 were analyzed. Of these patients, 93 (17%) were women with TNBC. Ten medical records were excluded, and the final sample was composed of 83 women with TNBC. OS and DFS were estimated by the Kaplan-Meier model. Univariate analysis (log-rank test) and multivariate analysis (Cox regression) were used to examine prognostic factors related to a statistically significant reduction (p<0.05) in OS and DFS and increased risk of mortality and tumor recurrence.RESULTS: Smoking, advanced clinical stage, larger tumor size, angiolymphatic invasion, positive sentinel lymph node, axillary node involvement, higher cancer burden, surgical treatment with mastectomy, and recurrence were related to a significant decrease in OS and/or DFS and increased risk of mortality and/or recurrence in TNBC. The 10-year OS and DFS was around 61 and 65%, respectively. CONCLUSIONS: Advanced clinical stage, positive sentinel lymph node, axillary node involvement, surgical treatment with mastectomy, and higher residual cancer burden were related to a significant reduction in OS and DFS and increased risk of mortality and recurrence in TNBC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic factors in triple-negative breast cancer: a retrospective cohort

Costa

Oliveira

Araújo³

et al. 2021

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

show abstract

“…Triple-negative BC (TNBC) is a subtype of BC, which accounts for 10–20% of cases of BC globally. TNBC is characterized by negative expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2, and is considered an independent clinicopathological type of cancer that is characterized by strong invasiveness (3–5). Metastasis is a critical biological hallmark of malignant tumors and is the leading cause of mortality among patients with TNBC (6–8); however, the specific process and underlying mechanism remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of miR‑214 attenuates the migration and invasion of triple‑negative breast cancer cells

Zhang

Zhao

et al. 2019

Mol Med Report

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) is a subtype of breast cancer. MicroRNA (miR)-214 is closely associated with controlling the development of tumor cells; therefore, in the present study, the target gene and effects of miR-214 on TNBC cells were explored. Luciferase activity was examined by luciferase reporter assay. The viability, invasion and migration of MDA-MB-231 TNBC cells were measured using Cell Counting kit-8, Transwell and wound-healing assays, respectively. The expression levels of various factors were determined using reverse transcription-quantitative polymerase chain reaction and western blotting. The results demonstrated that the expression levels of miR-214 were higher and the levels of α1-antitrypsin (α1-AT) were lower in TNBC tissues compared with in normal tissues. Subsequently, α1-AT was revealed to be a target of miR-214. Furthermore, inhibition of miR-214 decreased cell viability, invasion and migration, enhanced the expression of E-cadherin and tissue inhibitor of metalloproteinases-2, and reduced the expression of metastatic tumour antigen 1 and matrix metalloproteinase-2. Inhibition of miR-214 also significantly downregulated the phosphorylation of protein kinase B (Akt) and mammalian target of rapamycin (mTOR), and markedly downregulated that of phosphoinositide 3-kinase (PI3K); however, the expression levels of total PI3K, Akt and mTOR remained stable in all groups. Taken together, these findings indicated that α1-AT may be a target of miR-214. Downregulation of miR-214 markedly suppressed the viability, migration and invasion of MDA-MB-231 cells, and inhibited the PI3K/Akt/mTOR pathway. These findings suggested that miR-214 targeting α1-AT may be a potential mechanism underlying TNBC development.

show abstract

“…Correlation analysis determined that MAPK was significantly associated with EGFR expression, suggesting that MAPK and EGFR may act synergistically to promote TNBC progression. Lymph node metastasis and TNM staging are important for evaluating clinical prognosis in patients with TNBC (21), and can provide a basis for the selection of treatment options (22). The present study determined that in patients with TNBC, both MAPK and EGFR expression were significantly associated with both lymph node metastasis and clinical stage.…”

Section: Discussionmentioning

confidence: 59%

Expression and clinical significance of MAPK and EGFR in triple‑negative breast cancer

et al. 2020

View full text Add to dashboard Cite

To investigate the expression and clinical significance of mitogen-activated protein kinase (MAPK) and epidermal growth factor receptor (EGFR) in triple-negative breast cancer (TNBC), a total of 300 TNBC and 120 paired paracancerous tissues were examined. Immunohistochemistry was conducted to determine the expression levels of MAPK and EGFR, and the correlation between MAPK and EGFR expression was evaluated using Cramer's V test. The association between MAPK and EGFR expression, and various clinicopathological variables (such as lymph node metastasis, clinical stage, recurrence and metastasis) was also evaluated, using the χ 2 test. MAPK and EGFR expression levels in TNBC tissues were significantly higher than in the paired paracancerous tissues. Moreover, MAPK expression was associated with that of EGFR in TNBC tissues. The positive expression rates of MAPK and EGFR in patients with lymph node metastasis, advanced clinical stage, tumor recurrence and metastasis were higher than those without. Patients with positive expression of MAPK and EGFR in TNBC tissues had poorer prognoses and lower overall survival times than those without expression. In summary, the expression of MAPK and EGFR is closely associated with tumor invasion and the metastasis of TNBC, and may therefore be used as an indicator of poor prognosis in patients with TNBC.

show abstract

Prognostic value of Ki-67 according to age in patients with triple-negative breast cancer

Abstract: Prognostic value of Ki-67 in TNBC, using a cut-off point of 60%, may vary depending on age.

Cited by 17 publications

References 18 publications

Prognostic factors in triple-negative breast cancer: a retrospective cohort

Prognostic factors in triple-negative breast cancer: a retrospective cohort

Inhibition of miR‑214 attenuates the migration and invasion of triple‑negative breast cancer cells

Expression and clinical significance of MAPK and EGFR in triple‑negative breast cancer

Contact Info

Product

Resources

About